The Efficacy of Whole Genome Sequencing and RNA-Seq in the Diagnosis of Whole Exome Sequencing Negative Patients with Complex Neurological Phenotypes

Abstract

Whole-genome sequencing (WGS) is being increasingly utilized for the diagnosis of neurological disease by sequencing both the exome and the remaining 98 to 99% of the genetic code. In addition to more complete coverage, WGS can detect structural variants (SVs) and intronic variants (SNVs) that cannot be identified by whole exome sequencing (WES) or chromosome microarray (CMA). Other multi-omics tools, such as RNA sequencing (RNA-Seq), can be used in conjunction with WGS to functionally validate certain variants by detecting changes in gene expression and splicing. The objective of this retrospective study was to measure the diagnostic yield of duo/trio-based WGS and RNA-Seq in a cohort of 22 patients (20 families) with pediatric onset neurological phenotypes and negative or inconclusive WES results in lieu of reanalysis. WGS with RNA-Seq resulted in a definite diagnosis of an additional 25% of cases. Sixty percent of these solved cases arose from the identification of variants that were missed by WES. Variants that could not be unequivocally proven to be causative of the patients' condition were identified in an additional 5% of cases.

Keywords

transcriptome - genome - whole genome sequencing - whole exome sequencing - RNA-Seq

Publication History

Received: 16 March 2021

Accepted: 20 September 2021

Article published online:
09 November 2021

• References

• 1 Srivastava S, Love-Nichols JA, Dies KA. et al; NDD Exome Scoping Review Work Group. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med 2019; 21 (11) 2413-2421
• 2 Miller DT, Adam MP, Aradhya S. et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86 (05) 749-764
• 3 Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can exome sequencing do for you?. J Med Genet 2011; 48 (09) 580-589
• 4 Antonarakis SE, Krawczak M, Cooper DN. The Nature and Mechanisms of Human Gene Mutation. The Metabolic and Molecular Bases of Inherited Disease. 8th ed.. New York: McGraw-Hill; 2001: 343-377
• 5 Mattick JS, Dinger M, Schonrock N, Cowley M. Whole genome sequencing provides better diagnostic yield and future value than whole exome sequencing. Med J Aust 2018; 209 (05) 197-199
• 6 Barbitoff YA, Polev DE, Glotov AS. et al. Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage. Sci Rep 2020; 10 (01) 2057
• 7 Belkadi A, Bolze A, Itan Y. et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci U S A 2015; 112 (17) 5473-5478
• 8 Odgerel Z, Sonti S, Hernandez N. et al. Whole genome sequencing and rare variant analysis in essential tremor families. PLoS One 2019; 14 (08) e0220512
• 9 Alfares A, Aloraini T, Subaie LA. et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. Genet Med 2018; 20 (11) 1328-1333
• 10 Gilissen C, Hehir-Kwa JY, Thung DT. et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014; 511 (7509): 344-347
• 11 Lionel AC, Costain G, Monfared N. et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med 2018; 20 (04) 435-443
• 12 Piskol R, Ramaswami G, Li JB. Reliable identification of genomic variants from RNA-seq data. Am J Hum Genet 2013; 93 (04) 641-651
• 13 Wai HA, Lord J, Lyon M. et al; Splicing and disease working group. Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance. Genet Med 2020; 22 (06) 1005-1014
• 14 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 15 Dolzhenko E, van Vugt JJFA, Shaw RJ. et al; US–Venezuela Collaborative Research Group. Detection of long repeat expansions from PCR-free whole-genome sequence data. Genome Res 2017; 27 (11) 1895-1903
• 16 Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc 2016; 11 (09) 1650-1667
• 17 Ferdinandusse S, Falkenberg KD, Koster J. et al. ACBD5 deficiency causes a defect in peroxisomal very long-chain fatty acid metabolism. J Med Genet 2017; 54 (05) 330-337
• 18 Boczonadi V, Müller JS, Pyle A. et al. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nat Commun 2014; 5: 4287
• 19 Fagerberg CR, Taylor A, Distelmaier F. et al. Choline transporter-like 1 deficiency causes a new type of childhood-onset neurodegeneration. Brain 2020; 143 (01) 94-111
• 20 Castiglioni C, Fattori F, Udd B. et al. Neuromyopathy with congenital cataracts and glaucoma: a distinct syndrome caused by POLG variants. Eur J Hum Genet 2018; 26 (03) 367-373
• 21 Stavropoulos DJ, Merico D, Jobling R. et al. Whole genome sequencing expands diagnostic utility and improves clinical management in pediatric medicine. NPJ Genom Med 2016; 1: 15012
• 22 Taylor JC, Martin HC, Lise S. et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet 2015; 47 (07) 717-726
• 23 Clark MM, Stark Z, Farnaes L. et al. A meta-analysis of the diagnostic sensitivity and clinical utility of genome sequencing, exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genomic Medicine 2018; 3: 16 DOI: 10.1038/s41525-018-0053-8.
• 24 Farnaes L, Hildreth A, Sweeney NM. et al. Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization. NPJ Genom Med 2018; 3: 10
• 25 Lazaridis KN, Schahl KA, Cousin MA. et al. Outcome of whole exome sequencing for diagnostic odyssey cases of an individualized medicine clinic: the Mayo Clinic experience. Paper presented at: Mayo Clinic Proceedings. Elsevier; 2016: 297-307
• 26 Sawyer SL, Hartley T, Dyment DA. et al; FORGE Canada Consortium, Care4Rare Canada Consortium. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clin Genet 2016; 89 (03) 275-284
• 27 Dillon OJ, Lunke S, Stark Z. et al; Melbourne Genomics Health Alliance. Exome sequencing has higher diagnostic yield compared to simulated disease-specific panels in children with suspected monogenic disorders. Eur J Hum Genet 2018; 26 (05) 644-651
• 28 Wilfert AB, Sulovari A, Turner TN, Coe BP, Eichler EE. Recurrent de novo mutations in neurodevelopmental disorders: properties and clinical implications. Genome Med 2017; 9 (01) 101
• 29 Pitceathly RD, Tomlinson SE, Hargreaves I. et al. Distal myopathy with cachexia: an unrecognised phenotype caused by dominantly-inherited mitochondrial polymerase γ mutations. J Neurol Neurosurg Psychiatry 2013; 84 (01) 107-110
• 30 Fang M, Shen Z, Huang S. et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010; 143 (05) 711-724
• 31 Repp BM, Mastantuono E, Alston CL. et al. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?. Orphanet J Rare Dis 2018; 13 (01) 120
• 32 Gorcenco S, Ilinca A, Almasoudi W. et al. Invited review-Highlights of 2019 congress new generation genetic testing entering the clinic. Parkinsonism Relat Disord 2020; 73: 72-84